Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics
Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics. // Asian Journal of Psychiatry. – URL: https://www.sciencedirect.com/science/article/pii/S1876201826003552?dgcid=rss_sd_all
Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics. Asian Journal of Psychiatry. https://www.sciencedirect.com/science/article/pii/S1876201826003552?dgcid=rss_sd_all
“Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics.” Asian Journal of Psychiatry.
@article{article37228,
title = {Nanodispersible cannabidiol (150 mg/mL) for generalized anxiety disorder: Comparative emerging clinical evidence with first-line anxiolytics and mechanistic insights from network pharmacology and pharmacogenomics},
journal = {Asian Journal of Psychiatry},
url = {https://www.sciencedirect.com/science/article/pii/S1876201826003552?dgcid=rss_sd_all}
}